ВЫРАЖЕННОСТЬ ИММУННОГО И АУТОИММУННОГО КОМПОНЕНТОВ ВОСПАЛЕНИЯ У ПАЦИЕНТОК С СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКОЙ, РЕВМАТОИДНЫМ АРТРИТОМ, ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА



DOI: http://dx.doi.org/10.25298/2221-8785-2019-17-4-445-452


Н. А. Башлакова (N. A. Bashlakova), Т. Д. Тябут (T. D. Tyabut), А. Е. Буглова (Buglova A. E.)

Аннотация


Обследованы 40 пациенток с системной красной волчанкой (СКВ), 45 – с ревматоидным артритом (РА), 22 – с ишемической болезнью сердца (ИБС), 54 женщины без анамнеза ревматического заболевания (РЗ) или ИБС. Определены уровни вч-СРБ, фибриногена (ФГ), ИЛ-6, ФНО-α, антител к окисленным липопротеидам низкой плотности (аОЛПНП), антифосфолипидных антител (аФЛ). У пациенток с СКВ и РА, несмотря на проводимую терапию, сохранялась лабораторная активность, что подтверждалось повышением уровней вч-СРБ, СОЭ, ФГ, ИЛ-6, ФНО-α. Установлены сходные качественные и количественные аутоиммунные изменения при СКВ и РА. Сходная концентрация антител к β2-гликопротеину1 подтверждала значимость аутоиммунного воспаления для развития субклинического атеросклероза при РЗ и асептического аутоиммунного воспаления при ИБС.

Ключевые слова


системная красная волчанка, ревматоидный артрит, ишемическая болезнь сердца, маркеры воспаления, цитокины, антифосфолипидные антитела

Полный текст:

Литература


Libby, P. Clinical implications of inflammation for cardiovascular primary prevention / P. Libby, F. Crea // Eur. Heart. J. – 2010. – Vol. 31, iss. 7. – P. 777-783. – doi: 10.1093/eurheartj/ehq022.

Libby P, Crea F. Clinical implications of inflammation for cardiovascular primary prevention. Eur. Heart. J. 2010;31(7):777-783. doi: 10.1093/eurheartj/ehq022.

Kahlenberg, J. M. Mechanisms of Premature Atherosclerosis in Rheumatoid Arthritis and Lupus / J. M. Kahlenberg, M. J. Kaplan //Ann. Rev. Med. – 2013. – Vol. 64. – P. 249-263. – doi: 10.1146/annurev-med-060911-090007.

Kahlenberg JM, Kaplan MJ. Mechanisms of Premature Atherosclerosis in Rheumatoid Arthritis and Lupus. Annu Rev. Med. 2013;64:249-263. doi: 10.1146/annurev-med-060911-090007.

Schoenfeld, S. R. The epidemiology of atherosclerotic cardiovascular dis-ease among patients with SLE: a systematic review / S. R. Schoenfeld, S. Kasturi, K. H. Costenbader // Semin. Arthr. Rheum. – 2013. – Vol. 43, iss. 7. – P. 77-95. – doi: 10.1016/j.semarthrit.2012.12.002.

Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. 2013;43(1):77-95. doi: 10.1016/j.semarthrit.2012.12.002.

Gabriel, S. E. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases / S. E. Gabriel, K. Michaud // Arthritis Res. Ther. – 2009. – Vol. 11, iss. 3. – Art. 229. – doi: 10.1186/ar2669.

Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res. Ther. 2009;11(3):229. doi:10.1186/ar2669.

Age apecific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study / S. Manzi [et al.] // Am. J Epidemiol. – 1997. – Vol.145, iss. 5. – P. 408-415. – doi: 10.1093/oxfordjournals.aje.a009122.

Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, D'Agostino RB, Kuller LH. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am. J. Epidemiol. 1997;145(5):408-415. doi: 10.1093/oxfordjournals.aje.a009122.

Ridker, P. M. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? / P. M. Ridker // Trans. Am. Clin. Climatol. Assoc. – 2013. – Vol. 124. – P. 174-190.

Ridker PM. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? Trans. Am. Clin. Сlimatol. Аassoc. 2013;124:174-190.

Иммунологические маркеры антифосфолипидного синдрома. Часть II – маркеры повреждения эндотелия, воспаления и активации клеточного иммунитета / Е. Н. Александрова [и др.] // Науч.-практ. ревматол. – 2010. – Т. 48, № 5. – С. 67-74.

Aleksandrova EN, Novikov AA, Reshetnyak TM, Nasonov EL. Immunolog-icheskie markery antifosfolipidnogo sindroma. Chast II – Markery povrezhdenija jendotelija, vospalenija i aktivacii kletochnogo immuniteta. Nauchno-prakticheskaja revmatologija. 2010;48(5):67-74. doi: 10.14412/1995-4484-2010-733. (Russian).

Насонов, Е. Л. Антифосфолипидный синдром / Е. Л. Насонов. – Москва : Литтерра, 2004. – 440 с. Nasonov EL. Antifosfolipidnyj sindrom. Moskva: Litterra; 2004. 440 p. (Russian)

Nasonov EL. Antifosfolipidnyj sindrom. Moskva: Litterra; 2004. 440 p. (Russian)

Acute myocardial infarction in young adults with Antiphospholipid syn-drome: report of two cases and literature review / L. Abid [et al.] // Pan. Afr. Med. J. 2011. – Vol. 8. – P. 13.

Abid L, Frikha F, Bahloul Z, Kammoun S. Acute myocardial infarction in young adults with Antiphospholipid syndrome: report of two cases and literature review. Pan. Afr. Med. J. 2011;8:13.

Immunoglobulin G (IgG) anticardiolipin antibodies and recurrent cardiovascular events. A systematic review and Bayesian meta-regression / D. Pastori [et al.] // Autoimmun. Rev. – 2019. – Vol. 18, iss. 5. – P. 519-525. – doi: 10.1016/j.autrev.2019.03.005.

Pastori D, Bucci T. Triggiani M, Ames PRJ, Parrotto S, Violi F, Pignatelli P, Farcomeni A. Immunoglobulin G (IgG) anticardiolipin antibodies and recurrent cardiovascular events. A systematic review and Bayesian meta-regression. Auto-immun. Rev. 2019;18(5):519-525 doi: 10.1016/j.autrev.2019.03.005.

Antiphospholipid antibodies in patients with myocardial infarction / G. Grosso [et al.] // Ann. Intern. Med. – 2019. – Vol. 170, iss. 4. – P. 277-280. – doi: 10.7326/M18-2130.

Grosso G, Sippl N, Kjellström B, Amara K, de Faire U, Elvin K, Lindahl B, Näsman P, Ryden L, Norhammar A, Svenungsson E. Antiphospholipid an-tibodies in patients with myocardial infarction. Ann. Intern. Med. 2019;170 (4):277-280. doi: 10.7326/M18-2130.

Impact of antiphospholipid syndrome and/or systemic lupus erythematosus on the long-term adverse cardiovascular outcomes in patients after percutaneous coronary intervention. A Systematic Review and Meta-analysis / P. K. Bundhun [et al.] // Medicine. – 2016. – Vol. 95, iss. 12. – P. 1-8. – doi: 10.1097/MD.0000000000003200.

Bundhun PK, Boodhoo KD, Long MY, Chen MH. Impact of antiphospholipid syndrome and/or systemic lupus erythematosus on the long-term adverse cardiovascular outcomes in patients after percutaneous coronary intervention. A Systematic Review and Meta-analysis. Medicine. 2016;95(12):1-8. doi: 10.1097/MD.0000000000003200.

Subclinical atherosclerosis in systemic lupus erythematosus and antiphos-pholipid syndrome: focus on 2GPI-specific T cell response / F. Conti [et al.] // Arterioscler Thromb. Vasc. Biol. – 2014. – Vol. 34, iss. 3. – P. 661-668. – doi: 10.1161/ATVBAHA.113.302680.

Conti F, Spinelli FR, Alessandri C, Pacelli M, Ceccarelli F, Marocchi E, Montali A, Capozzi A, Buttari B, Profumo E, Sorice M, Arca M, Valesini G, Rigano R. Subclinical atherosclerosis in systemic lupus erythematosus and antiphospholipid syndrome: focus on β2GPI-specific T cell response. Arterioscler Thromb. Vasc. Biol. 2014;34(3):661-668. doi: 10.1161/ATVBAHA.113.302680.

Does the presence of secondary antiphospholipid syndrome in patients with systemic lupus erythematodes accelerate carotid arteries intima-media thickness changes? / A. Djokovic [et al.] // Rheumatol. Int. – 2014. – Vol. 34, iss. 3. – P. 321-327. – doi: 10.1007/s00296-013-2903-0.

Djokovic A, Stojanovich Lj, Stanisavljevic N, Bisenic V, Radovanovic S, Soldatovic I, Simic DV. Does the presence of secondary antiphospholipid syn-drome in patients with systemic lupus erythematodes accelerate carotid arteries in-tima-media thickness changes? Rheumatol. Int. 2014;34(3):321-327. doi: 10.1007/s00296-013-2903-0.

Is atherosclerosis an autoimmune disease? / E. Matsuura [et al.] // BMC Medicine. – 2014. – Vol. 12. – P. 47-51. – doi: 10.1186/1741-7015-12-47.

Matsuura E, Atzeni F, Sarzi-Puttini P, Turiel M, Lopez LR, Nurmohamed MT. Is atherosclerosis an autoimmune disease? BMC Medicine. 2014;12:47-15. doi: 10.1186/1741-7015-12-47.

ESH-ESC Practice Guidelines for the Management of arterial Hypertension 2007 / European Society of Hypertension, European Society of Cardiology ; G. Mancia [et al.] // J. Hypertension. – 2007. – Vol. 25, iss. 9. – P. 1751-1762. – doi: 10.1097/HJH.0b013e3282f0580f.

Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Ryn-kiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A; European Society of Hypertension, European Society of Cardiology. 2007 ESH-ESC Practice Guidelines for the Management of arterial Hypertension. J. Hypertens. 2007;25(9):1751-1762. doi: 10.1097/HJH.0b013e3282f0580f.

Incidence and predictors of cardiovascular events in a cohort of patients with rheumatoid arthritis / A. M. Castro [et al.] // Acta Reumatol. Port. – 2016. – Vol. 41, iss. 3. – P. 213-219

Castro AM, Carmona-Fernandes D, Rodrigues AM, Pedro LM, Santos MJ, Canhão H, Fonseca JE. Incidence and predictors of cardiovascular events in a co-hort of patients with rheumatoid arthritis. Acta Reumatol. Port. 2016;41(3):213-219.

Predictors of cardiovascular demage in patients with systemic lupus erythe-matosus: data from LUMINA (LXVIII), a multiethnic US cohort. / J. P. Guillermo [et al.] // Rheumatology. – 2009. – Vol. 48, iss. 7. – P. 817-822. – doi: 10.1093/rheumatology/kep102.

Pons-Estel GJ, González LA, Zhang J, Burgos PI, Reveille JD, Vilá LM, Alarcón GS. Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort. Rheuma-tology. 2009;48(7):817-822. doi: 10.1093/rheumatology/kep102.

Macrophage activation and coronary atherosclerosis in systemic lupus ery-thematosus and rheumatoid arthritis / Y. H. Rho [et al.] // Arthritis Care Res. – 2011. – Vol. 63, iss. 4. – P.535-541. – doi: 10.1002/acr.20365.

Rho YH, Solus J, Raggi P, Oeser A, Gebretsadik T, Shintani A, Stein CM. Macrophage activation and coronary atherosclerosis in systemic lupus erythemato-sus and rheumatoid arthritis. Arthritis Care Res. 2011;63(4):535-541. doi: 10.1002/acr.20365.

Ревматология : национальное руководство / под ред. Е. Л. Насонова, В. А. Насоновой. – Москва : ГЭОТАР-Медиа, 2010. – 720 с.

Nasonov EL, Nasonova VA, editors. Revmatologija: nacionalnoe rukovodstvo. Moskva: GJeOTAR-Media; 2010. 720 p. (Russian).

Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study / J. Gustafsson [et al.] // Arthritis Res. Ther. – 2009. – Vol. 11, iss. 6. – R. 186. – doi: 10.1186/ar2878.

Gustafsson J, Gunnarsson I, Börjesson O, Pettersson S, Möller S, Fei GZ, Elvin K, Simard JF, Hansson LO, Lundberg IE, Larsson A, Svenungsson E. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus – a prospective cohort study. Arthritis Res. Ther. 2009;11(6):R186. doi: 10.1186/ar2878.

Subclinical atherosclerosis in patients with systemic lupus erythematosus: a systemic review and meta-analysis / G. C. Wu [et al.] // Autoimmun. Rev. – 2016. –Vol. 15, iss. 1. – P. 22-37. – doi: 10.1016/j.autrev.2015.10.002.

Wu GC, Liu HR, Leng RX, Li XP, Li XM, Pan HF, Ye DQ. Subclinical atherosclerosis in patients with systemic lupus erythematosus: A systemic review and meta-analysis. Autoimmun. Rev. 2016;15(1):22-37. doi: 10.1016/j.autrev.2015.10.002.

Prevalence of antiphospholipid antibodies in rheumatoid arthritis patients and relationship with disease activity / R. Jeleniewicz [et al.] // Pol. Arch. Med. Wewn. – 2012. – Vol. 122, iss. 10. – P. 480-486.

Jeleniewicz R, Majdan M, Targońska-Stępniak B, Dryglewska M. Preva-lence of antiphospholipid antibodies in rheumatoid arthritis patients and relation-ship with disease activity. Pol. Arch. Med. Wewn. 2012;122(10):480-486.

Association between antiphospholipid antibodies and arterial thrombosis in patients with rheumatoid arthritis / K. J. Kim [et al.] // Lupus. – 2017. – Vol. 26, iss. 1. – P.88-94. – doi:10.1177/0961203316658557.

Kim KJ, Baek IW, Park KS, Kim WU, Cho CS. Association between an-tiphospholipid antibodies and arterial thrombosis in patients with rheumatoid ar-thritis. Lupus. 2017;26(1):88-94. doi: 10.1177/0961203316658557.

Auto-antibodies do not influence development of atherosclerotic plaques in rheumatoid arthritis / I. Pereira [et al.] // Joint Bone Spine. – 2008. – Vol.75, iss. 4. – P. 416-421. – doi: 10.1016/j.jbspin.2008.01.022.

Pereira I, Laurindo I, Burlingame R, Anjos L, Viana V, Leon E, Vendramini M, Borba E. Auto-antibodies do not influence development of atherosclerotic plaques in rheumatoid arthritis. Joint Bone Spine. 2008;75(4):416-421. doi: 10.1016/j.jbspin.2008.01.022.

Antiphospholipid antibodies and atherosclerosis: insights from rheumatoid arthritis - a five-year follow-up study / I. Holc [et al.] // Immunobiology. – 2011. – Vol. 216, iss. 12. – P. 1331-1337. doi: 10.1016/j.imbio.2011.05.008.

Holc I, Hojs R, Cikeš N, Ambrožič A, Cučnik S, Kveder T, Rozman B, Pahor A. Antiphospholipid antibodies and atherosclerosis: insights from rheumatoid arthritis - a five-year follow-up study. Immunobiology. 2011;216(12):1331-1337. doi: 10.1016/j.imbio.2011.05.008.

The antiphospholipid syndrome in patients with systemic lupus erythematosus / G. J. Pons-Estel [et al.] // J. Autoimmun. – 2017. – Vol. 76. – P. 10-20. – doi: 10.1016/j.jaut.2016.10.004.

Pons-Estel GJ, Andreoli L, Scanzi F, Cervera R, Tincani A. The antiphos-pholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun. 2017;76:10-20. doi: 10.1016/j.jaut.2016.10.004.

Antiphospholipid antibodies as independent predictors of accelerate athero-sclerosis in systemic lupus etythematosus patients / L. Stojanovich [et al.] // Ann. Rheum. Dis. – 2015. – Vol. 74, suppl. 2. – P. 1-574.

Stojanovich L, Djokovic A, Todic B, Radovanovic S. Antiphospholipid an-tibodies as independent predictors of accelerate atherosclerosis in systemic lupus etythematosus patients. Ann. Rheum. Dis. 2015;74(Suppl 2):1-574.


Ссылки

  • На текущий момент ссылки отсутствуют.